Home » UK
Category Archives: UK
SEARCH THIS BLOG

Blog Stats
- 1,981,886 hits
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- MHLW JAPAN, 厚生労働省
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- April 2018 (14)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (42)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (120)
- African medicine (6)
- AIDS (7)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (33)
- ANTIBODIES (48)
- antimalarials (6)
- ARAB MEDICINE (5)
- Australia (1)
- AWARD (7)
- AYURVEDA (78)
- Biosimilar drugs (38)
- BLA (3)
- BLOGS (24)
- Breakthrough Therapy Designation (38)
- canada (4)
- cancer (128)
- cfda (6)
- china pipeline (28)
- CHINESE HERBS (24)
- CLINICAL TRIALS (10)
- COMPANIES (80)
- conference (4)
- Contrast agent (6)
- CRL (1)
- Dengue (1)
- DIABETES (41)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- EMA (4)
- EU 2014 (4)
- EU 2015 (2)
- EU 2016 (2)
- EU 2017 (7)
- EU 2018 (1)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK FDA (40)
- FDA 15 (3)
- FDA 2010 (1)
- FDA 2012 (5)
- FDA 2013 (5)
- FDA 2014 (50)
- FDA 2015 (34)
- FDA 2016 (21)
- FDA 2017 (57)
- FDA 2018 (7)
- Featured product (1)
- flow synthesis (14)
- FORMULATION (14)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (103)
- GENERICS (19)
- glenmark (17)
- GLENMARK (15)
- GMP (10)
- Greek medicine (3)
- Herbals (8)
- HOMEOPATHY (3)
- Human medicines European Public Assessment Report EPAR (2)
- IMPLANTS (2)
- IND 2018 (2)
- IND Filed (2)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2013 (1)
- JAPAN 2015 (2)
- japan 2017 (6)
- JAPAN 2018 (4)
- Japan marketing (31)
- Japan pipeline (35)
- Korea (2)
- korea 2016 (1)
- MAA (3)
- Malaria (16)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (8)
- Monoclonal antibody (68)
- Nanotechnology (5)
- NCE (2)
- NDA (52)
- NDA JAPAN (3)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- NUCLEOTIDES (1)
- organic chemistry (11)
- PATENT (91)
- PATENTS (80)
- Peptide drugs (14)
- PFIZER (1)
- PHASE 1 (53)
- PHASE1 (118)
- Phase2 drugs (217)
- Phase3 drugs (247)
- POLYMORPH (10)
- Preclinical china (9)
- Preclinical drugs (106)
- Premture ejaculation (3)
- Priority review (37)
- PROCESS (36)
- Promising clips (8)
- QbD (2)
- QIDP (16)
- RADIOLABELLED (7)
- Rare disease (3)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- spectroscopy (16)
- SPOTLIGHT (52)
- Stem cells (3)
- SYNTHESIS (10)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (1,931)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (8)
- veterinary (2)
- VITAMINS (2)
Recent Posts
- Cadexomer Iodine April 18, 2018
- Clofarabine April 18, 2018
- FDA approves first therapy Crysvita (burosumab) for rare inherited form of rickets, x-linked hypophosphatemia April 18, 2018
- WO 2018066004, NEW PATENT, INDOCO REMEDIES LIMITED, DORZOLAMIDE April 17, 2018
- WO 2018067805, NEW PATENT, SOTAGLIFLOZIN, TEVA April 17, 2018
- BMS-986118, for treatment for type 2 diabetes( GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion) April 13, 2018
- BMS-986195 April 12, 2018
- Anagrelide アナグレリド , April 11, 2018
- VNRX-5133 from VENATORX PHARMACEUTICALS April 10, 2018
- Catalyst-free and solvent-free hydroboration of aldehydes — All About Drugs April 6, 2018
- 4,4,5,5-Tetramethyl-2-phenethyl-1,3,2-dioxaborolane — ORGANIC SPECTROSCOPY INTERNATIONAL April 6, 2018
- High vitamin D levels may help prevent cancer — Med-Chemist April 6, 2018
- JNJ-54861911, Atabecestat , атабецестат , أتابيسيستات , April 6, 2018
- LY 3104607 April 4, 2018
- FDA expands approval of Blincyto (blinatumomab) for treatment of a type of leukemia in patients who have a certain risk factor for relapse March 30, 2018
ORGANIC SPECTROSCOPY

SUBSCRIBE

Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by EmailDR ANTHONY MELVIN CRASTO Ph.D
DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 year tenure till date Dec 2017, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 50 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 19 lakh plus views on New Drug Approvals Blog in 216 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc
Personal Links
- my sites on the net
- DR ANTHONY MELVIN CRASTO
- GOOGLE GROUP ORGANIC PROCESS DEVELOPMENT
- mixxt
- epernicus
- scipeople
- jimdo
- yolasite
- my cv
- slidestaxx
- wordpress blog
- ABOUT ME
- BRANDSITE
- SKILLPAGES
- Academia.edu
- DIIGO
- WIX
- WIX BLOG
- ISSUU
- SCRIBD
- BIZ
- GOOGLE BLOG
- APNACIRCLE
- Eurekamoments in Organic Chemistry
- Organic Chemistry by Dr Anthony
- Green Chemistry International
- Technology Transfer
- Stereochemistry
- Spectroscopy
- Polymorphism
- Reactions in Org Chem
- DR ANTHONY MELVIN CRASTO Ph.D
- Pharmaceuticals
- Medicinal chemistry
- Organic chemistry literature
- Patent related site
- Green chemistry
- Reagents
- R & D
- Molecules
- Heterocyclic chem
- Sourcing
- NEW DRUG APPROVALS
- WORLD DRUG TRACKER
- Green Chemistry International
- drug regulatory affairs international
- ORGANIC SPECTROSCOPY INTERNATIONAL
- ORGANIC SYNTHESIS INTERNATIONAL
- ALL ABOUT DRUGS
- ORGANIC CHEMISTRY INTERNATIONAL
- GOOGLE PLUS
- Drug Scaleup and Manufacturing International
- MEDICINAL CHEMISTRY INTERNATIONAL
- DRUG SYNTHESIS INTERNATIONAL
- SLIDESHARE
- DRUGS WEB
- GOOGLE SCHOLAR
- MEDCHEM-amcrasto
- ONE ORGANIC CHEMISTONE DAY
- DRUG PATENTS INTERNATIONAL
- MEDCHEM ANTHONY CRASTO
- MEDCHEM anthony crasto
- Gravatar
- ZING ME VIETNAM
- RESEARCH GATE
- AWARDS
Verified Services
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- MHLW JAPAN, 厚生労働省
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- April 2018 (14)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (42)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (120)
- African medicine (6)
- AIDS (7)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (33)
- ANTIBODIES (48)
- antimalarials (6)
- ARAB MEDICINE (5)
- Australia (1)
- AWARD (7)
- AYURVEDA (78)
- Biosimilar drugs (38)
- BLA (3)
- BLOGS (24)
- Breakthrough Therapy Designation (38)
- canada (4)
- cancer (128)
- cfda (6)
- china pipeline (28)
- CHINESE HERBS (24)
- CLINICAL TRIALS (10)
- COMPANIES (80)
- conference (4)
- Contrast agent (6)
- CRL (1)
- Dengue (1)
- DIABETES (41)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- EMA (4)
- EU 2014 (4)
- EU 2015 (2)
- EU 2016 (2)
- EU 2017 (7)
- EU 2018 (1)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK FDA (40)
- FDA 15 (3)
- FDA 2010 (1)
- FDA 2012 (5)
- FDA 2013 (5)
- FDA 2014 (50)
- FDA 2015 (34)
- FDA 2016 (21)
- FDA 2017 (57)
- FDA 2018 (7)
- Featured product (1)
- flow synthesis (14)
- FORMULATION (14)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (103)
- GENERICS (19)
- glenmark (17)
- GLENMARK (15)
- GMP (10)
- Greek medicine (3)
- Herbals (8)
- HOMEOPATHY (3)
- Human medicines European Public Assessment Report EPAR (2)
- IMPLANTS (2)
- IND 2018 (2)
- IND Filed (2)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2013 (1)
- JAPAN 2015 (2)
- japan 2017 (6)
- JAPAN 2018 (4)
- Japan marketing (31)
- Japan pipeline (35)
- Korea (2)
- korea 2016 (1)
- MAA (3)
- Malaria (16)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (8)
- Monoclonal antibody (68)
- Nanotechnology (5)
- NCE (2)
- NDA (52)
- NDA JAPAN (3)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- NUCLEOTIDES (1)
- organic chemistry (11)
- PATENT (91)
- PATENTS (80)
- Peptide drugs (14)
- PFIZER (1)
- PHASE 1 (53)
- PHASE1 (118)
- Phase2 drugs (217)
- Phase3 drugs (247)
- POLYMORPH (10)
- Preclinical china (9)
- Preclinical drugs (106)
- Premture ejaculation (3)
- Priority review (37)
- PROCESS (36)
- Promising clips (8)
- QbD (2)
- QIDP (16)
- RADIOLABELLED (7)
- Rare disease (3)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- spectroscopy (16)
- SPOTLIGHT (52)
- Stem cells (3)
- SYNTHESIS (10)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (1,931)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (8)
- veterinary (2)
- VITAMINS (2)
Recent Comments
SEARCH THIS BLOG
UK launch for Astellas’ prostate cancer drug
July 20, 2013 3:50 am / Leave a comment
http://www.pharmatimes.com/Article/13-07-19/UK_launch_for_Astellas_prostate_cancer_drug.aspx
UK patients with advanced prostate cancer have been given access to a new treatment that could prolong survival following the launch of Astella’s Xtandi in the country.
Xtandi (enzalutamide) was licensed in Europe this month for the treatment of men with advanced prostate cancer whose disease has become resistant to first-line hormonal treatments and has progressed following docetaxel chemotherapy.
Enzalutamide is an androgen receptor inhibitor. The chemical name is 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide.
The molecular weight is 464.44 and molecular formula is C21H16F4N4O2S. The structural formula is:
![]() |
Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water.
XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.